Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
177
resultados
Última actualización
04/05/2025 [07:05:00]
Resultados 150 a 175 de 177
Resumen de: US2025087324A1
A system and method that enables users to provide authenticated medical records (e.g., vaccination records, viral anti-body test results, etc.) to a third-party (e.g., a venue) to gain access to the third-party is provided. In this way, the third party may confirm that the user is sufficiently immune to a particular disease (e.g., COVID-19) and may thereby minimize the threat of the user introducing the contagious disease to the third party. The system includes a biometric data recognition system that authenticates the identity of a user, a medical records acquisition system that acquires the medical records of the authenticated user, and a system for the displaying or otherwise providing the medical records to the third-party for review. The system also includes a system identification card that includes the user's contact information, alphanumeric characters associated with the user's driver's license number, medical records of the user, and other elements.
Resumen de: AU2023346793A1
The present disclosure relates to the use of compounds such as compounds of Formula (I) or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, for example, in pharmaceutical compositions and in the treatment of diseases, disorders or conditions such as diseases, disorders or conditions treatable by inhibiting SWAP-70 and/or treatable by inhibiting neutrophil reactive oxygen species (ROS) production, neutrophil NETosis, B lymphocyte plasmablast development, B lymphocyte IgE production, mast cell degranulation, eosinophil ROS production, mast cell cytokine release, B lymphocyte cytokine release, endothelial cell cytokine release, endothelial cell-immune cell interactions, and/or macrophage/monocyte migration, such as treatment of lung inflammation induced by viruses such as SARS-CoV-2.
Resumen de: WO2025054236A2
Provided herein are SARS-CoV-2 spike proteins and polypeptides (e.g., SARS-CoV-2 spike proteins and polypeptide immunogens (and immunogenic fragments and immunogenic variants thereof)) comprising at least one non-naturally occurring glycosylation site, and nucleic acid molecules encoding the same. Further provided herein are compositions (e.g., pharmaceutical compositions) and vaccines comprising the same for use in e.g., the prevention, treatment, and/or amelioration of a SARS-CoV-2 infection.
Resumen de: WO2025054605A1
The disclosure provides methods for rapidly detecting SARS-CoV-2 in patient samples, especially for diagnosis, treatment, and epidemiological tracking. The methods comprise using specific PCR primers to amplify a sequence from the viral nucleocapsid phosphoprotein coding region. The methods provide a rapid, effective, and highly sensitive way to detect the virus in patient samples.
Resumen de: US2024376178A1
The invention relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.
Resumen de: AU2023265164A1
The disclosure provides, in various embodiments, polypeptides (
Resumen de: US2024376178A1
The invention relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.
Resumen de: MX2024013366A
The invention relates to a method of enhancing immunity, mRNA-based vaccines for SARS-CoV-2 have demonstrated the enormous potential of mRNA therapeutics for safe and effective use in the general population. However, more recent studies have demonstrated decreasing vaccine effectiveness in terms of asymptomatic infection as well as symptomatic and severe infections starting around 4 months post second dose with mRNA-lipid nanoparticles (LNP) based regimens.
Resumen de: US2025073259A1
A therapeutic material active against SARS-COV 2 and other microbial pathogens and method of administering the same.
Resumen de: AU2023334060A1
The present disclosure is directed to antibodies and antigen binding fragments thereof, or combinations of antibodies and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. The disclosure contemplates conjugates of anti-CoV-S antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the disclosure contemplate using anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses or the S protein thereof and conditions where neutralization or inhibition of coronaviruses or the S protein thereof would be therapeutically beneficial.
Resumen de: AU2023336178A1
The invention relates to a polynucleotide encoding a) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein; and/or b) at least one non-structural SARS-CoV-2 protein selected from the group consisting of non-structural protein 7, non-structural protein 8, non-structural protein 9, non-structural protein 10, non-structural protein 11, non-structural protein 12, an endoribonuclease, and a 2'-O-methyltransferase, wherein the polynucleotide comprises or consists of at least one sequence part comprising codon-pair deoptimizations in comparison to the SARS-CoV-2 genome, and wherein the polynucleotide further comprises a furin cleavage site modification resulting in a loss of a furin cleavage site being naturally present in the SARS-CoV-2 genome. The invention further relates to a live attenuated SARS- CoV-2 comprising this polynucleotide, to a vaccine comprising this live attenuated SARS-CoV-2, as well as to associated methods.
Resumen de: AU2023313034A1
The disclosure provides compositions and methods comprising selective inhibitors of Rho-associated coiled-coil kinase 2 (ROCK2) for use in the treatment of viral infections, particularly coronavirus infections such as SARS-CoV-2, and in the treatment of sequelae resulting from the viral infection, including sequelae resulting from coronavirus infection.
Resumen de: US2025073163A1
The present invention provides a method of treating an infectious disease. The method comprises the step of administering to a subject in need thereof an effective amount of (i) a polymer-flavonoid conjugate, (ii) a flavonoid oligomer, or (iii) micelles having a shell formed by one or more polymer-flavonoid conjugates or one or more flavonoid oligomers, or the combination thereof, and having an agent encapsulated within the shell. The present method is effective to treat viral infection, e.g., severe acute respiratory syndrome coronavirus (SARS-CoV), enterovirus virus, HIV, hepatitis B virus, MERS-CoV, influenza virus, Dengue virus, respiratory syncytial virus, hepatitis C virus, monkeypox virus, human papillomavirus, methicillin-resistant Staphylococcus aureus, Pseudomonas, tuberculosis, Bacillus anthracis, Tetani bacterium, Streptococcus pneumoniae, meningococcus, Escherichia coli, Legionella, Neisseria gonorrhea, Neisseria meningitidis, and Salmonella.
Resumen de: US2025074938A1
Provided are protease inhibitor compounds that find use in treating or preventing coronavirus disease. In some embodiments, the coronavirus disease is COVID-19. Also provided are compositions and kits comprising the compounds, as well methods of using the compounds to treat or prevent coronavirus disease. Also provided are methods for reporting coronaviral protease inhibition.
Resumen de: US2025074907A1
Described herein are compounds, and methods for the treatment of coronavirus infection.
Resumen de: US2025076294A1
A rapid test device for the detection of SARS-CoV-2 viruses and for the relative antibody production including a substrate of the lateral flow immunochromatographic assay divided into 5 regions: a first reception area to receive the biological sample (“Sample Deposition”); a second area where the first reaction takes place between an analyte and the molecule used for its specific identification (“Conjugation pad”); a third area where the signal amplification uses the addition of the gold nanoparticles (“Signal amplification”); a fourth test area (“Test line”) and a fifth control area (“Control Line”) in which a second and third immunoreaction takes place, providing a visual reading of the test result by a window and two results visible by a colored strip. The sample deposition area comprises a filter having porosity of about 200 nm-1 μm.
Resumen de: US2025079025A1
A pathogen test device, including a center body to facilitate gripping thereof, a swab connected to at least a portion of a first end of the center body to absorb at least one fluid therein in response to contact with the at least one fluid, a testing container detachably connected to at least a portion of a second end of the center body to store a testing liquid therein, and a test display disposed on at least a portion of the center body to display a test result identifying a presence of at least one of COVID-19, strep, and control in response to inserting the swab with the at least one fluid into the testing container.
Resumen de: WO2025049355A1
Disclosed herein are compositions comprising nanoparticles designed for CRISPR/Cas13 RNA targeting systems, specifically aimed at targeting poorly druggable, disease-driving genes in prostate cancer and COVID-19, and methods of use thereof.
Resumen de: WO2025049225A2
Diagnostic assay devices for detecting the presence of an analyte in a sample solution may comprise a microreactor configured to form a sample solution containing the analyte, flow the sample solution therethrough in a first direction to form an analyte-capture molecule complex, and transfer the sample solution to an absorbent strip pad configured to flow therethrough, in a second direction crossing the first direction, the sample solution including the analyte-capture molecule complex and indicate a presence of the analyte-capture molecule complex. In some embodiments the devices are configured to process a bioaerosol sample. In some embodiments the diagnostic assay devices may be multiplexed and may be used for detecting the presence of two or more analytes in a sample solution. The diagnostic devices may be used, for example, to identify the presence of one or more of SARS-Cov2, RSV, influenza A, influenza B or other pathogens in samples from patients.
Resumen de: WO2025046629A1
The present disclosure relates to in vitro identification of neutralizing antibody against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Specifically, the present disclosure relates a kit and an in vitro assay for analyzing the presence of neutralizing antibody/inhibitors which could block or inactivate receptor binding domain of the spike protein of SARS-CoV-2.
Resumen de: WO2025046130A2
The present invention relates to polypeptides, polynucleotides, compositions, microorganisms, vectors and vaccine compositions optimised for the treatment or prophylaxis of a disease or infection caused by Betacoronaviruses, including but not limited to: Embecovirus, Hibecovirus, Merbecovirus, Nobecovirus, Sarbecovirus, MERS-CoV, SARS-CoV-1 and SARS-CoV-2. In particular, the invention provides a vaccine composition comprising a polypeptide, wherein the polypeptide comprises one or more epitope sequences, wherein the one or more epitope sequences have the amino acid sequences of any one or more of the sequences of Table 1, or a variant thereof having at least 70% sequence identity thereto, and wherein the polypeptide sequence is no more than 1400 amino acids in length.
Resumen de: WO2025049305A1
The invention relates to methods and kits for determining a SARS-CoV-2 strain in a sample. The invention also provides methods and kits for detecting a single nucleotide polymorphism (SNP) in a target nucleic acid, wherein the target nucleic acid is a SARS-CoV-2 nucleic acid. The invention further provides methods and kits for detecting one or more antibody biomarkers in a sample.
Resumen de: SA522441481B1
Compositions and use of the compositions in methods of detecting SARS-CoV-2 in a sample is disclosed, using RT-LAMP coupled with CRISPR-Cas12, referred to herein as iSCAN (in vitro Scanning of COVID-19-Associated Nucleic acids) is disclosed. iSCAN provides a rapid, specific, accurate, sensitive detection of SARS-CoV-2 in a sample. The iSCAN is 1) rapid, as the RT-LAMP and CRISPR-Cas12/Cas 13 reaction takes less than 1 h; 2) specific, because detection depends on the identification and subsequent cleavage of SARS-CoV-2 genomic sequences by the Cas12 or 13 enzyme; 3) field-deployable, as only simple equipment is required; and 4) easy to use, as the colorimetric reaction coupled to lateral flow immunochromatography makes the assay results easy to assess. The methods include amplifying SARS-CoV-2 in a sample using RT-LAMP and using the RT-LAMP product as a substrate in a CRISPR-Cas12/13 reaction, incorporated with a means of detecting the presence of the SARS-CoV-2 RT-LAMP product. Fig
Resumen de: EP4516931A1
The present disclosure relates to a composition for preventing or treating coronavirus infection, including a hotspot-derived peptide-nucleic acid hybrid molecule. It was confirmed that in vitro evolution-based hotspot-derived peptide-nucleic acid hybrid molecule prepared using the method of the present invention has high binding affinity for the RBDs of SARS-CoV-2 VOCs (alpha, beta, gamma, delta, and omicron). In particular, it was found that the greatest binding tolerance was exhibited in the most highly mutated omicron. Furthermore, the hybrid molecule showed high RBD binding affinity in competition with RBD-binding nucleic acid aptamers, macrocyclic peptides, and monoclonal antibodies. The hybrid molecule also exhibited excellent nuclease resistance and serum stability, indicating potential as virus neutralizer in addition to SARS-CoV-2.
Nº publicación: EP4514842A1 05/03/2025
Solicitante:
ASTRAZENECA UK LTD [GB]
AstraZeneca UK Limited
Resumen de: AU2023262192A1
The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of making and using the same. The antibodies can be used, for example, in prophylaxis, post-exposure prophylaxis, or treatment of SARS-CoV-2 infection. The antibodies can also be used to detect SARS-CoV-2, e.g., an infection in subject.
BOPI
Sede Electrónica
